Desert Oasis Healthcare

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Obesity4 trials
• Type 2 diabetes3 trials
• Heart failure2 trials
• Osteoarthritis1 trial
• Type 1 diabetes1 trial

Phase

• Phase 36 trials

Status

• Completed3 trials
• Recruiting3 trials
• Active, not recruiting1 trial

Lead sponsor

• Novo Nordisk A/S6 trials
• Analog Device, Inc.1 trial

Running trials

• Recruiting

  A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

  NCT07668414· Phase 3· Novo Nordisk A/S· Source

  Contact: Novo Nordisk

• Recruiting

  A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

  NCT07564414· Phase 3· Novo Nordisk A/S· Source

  Contact: Novo Nordisk

• Recruiting

  A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  NCT07567001· Phase 3· Novo Nordisk A/S· Source

  Contact: Novo Nordisk

• Recruiting

  AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

  NCT07509307· Phase 3· Novo Nordisk A/S· Source

  Contact: Novo Nordisk

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity3 recruiting
• Heart failure1 recruiting
• Osteoarthritis1 recruiting

Closed trials

• Completed

  A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both

  NCT06534411· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

  NCT06221969· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  Feasibility and Efficacy Study of the CardioPulmonary Management (CPM) System in Patients With Chronic Heart Failure

  NCT05650541· Analog Device, Inc.· Source

  Contact: Emily Wycallis